

FIG. 1.





FIG. 2.



- Onconase, Daudi
- Onconase, CA-46
- LL2-Onconase, Daudi
- LL2-Onconase, CA-46

FIG. 3.






FIG. 4.

**The Effect of LL2-Onc vs LL2-hPanc on
Daudi Lymphoma cells**



% Retained on Daudi Cells




FIG. 5A.

% Degraded





FIG. 5B.

LL2-EDN
LL2-Onconase
LL2

FIG. 6.



7/9

MPT Daudi/i.v. in SCID mice, I20996




FIG. 7.

FIG. 8.





FIG. 9.



- LL2-Onc, 300 mg/kg
- Onc, 25 mg/kg
- ▽— Onc, 30 mg/kg
- ◇— PBS
- IT-dgRTA, 50 mg/kg

Drugs administered every 2 h
4x/day for 5 days. The arrows
indicate the days the mice with
each respective treatment were
found dead.

RFB4-PE35KDEL, 1 x/day for 4 days: LD50 1 mg/kg